Issue link: https://cp.revolio.com/i/541817
Page 20 | Abby's Magazine - www.AbbysMag.com T here is no question about the benefits of hormone replacement therapy for those who actually need it. However, there is an ongoing debate about HRT (synthetic hormones) and BHRT (bioidentical hormones) (Reference: W. Faloon. "The Unscientific Bioidentical Hormone Debate." Life Extension Magazine. Oct 2009). Men and women who suffer from hormone deficiency (andropause or menopause) do need the beneficial effects of hormones. However, a one-size-fits-all approach in hormone therapy may provide more harm than good to many patients. It is important to keep in mind that each individual's hormone needs vary and should be addressed accordingly. Even more important is the knowledge of cancer risks involved with excess hormone accumulation. Myomin for a Health Estrogen Quotient (E3 > E1 +E2) Among individuals on HRT or BHRT, there needs to be a balance among the different estrogens: estrone (E1), estradiol (E2) and estriol (E3). Studies show that E3, the weak estrogen, becomes an anticarcinogen in the presence of E1 and E2. Henry Lemon, who derived the estrogen quotient (EQ), figured out than an EG higher than 1 (meaning more E3 than E1 and E2 combined) signals lower cancer risk. Women need to check their EQ once they hit menopause in order to keep track of estrogen balance. Also if the breasts hurt after menopause, this is a sign of increased breast cancer risk, especially in women on HRT or BHRT. Men and women on any type of hormone therapy will benefit from adding Myomin to their regimen. Always remember that HRT or BHRT carries a risk of hyperaromatization. This happens when the aromatase enzyme converts androgens into estrogens excessively. Androstenedione and testosterone are directly converted to estrone and estradiol, respectively. Progesterone, pregnenolone, and DHEA, on the other hand, are all precursors of androgens and may also be converted into estrogens. Myomin helps minimize this conversion by reducing aromatase expression. As a result, it counteracts the harmful effects and risks associated with HRT or BHRT. Myomin for Men and Women on HRT or BHRT to Reduce Cancer Risk A new study has found that any type of hormone therapy increases a woman's breast cancer risk if taken for more than 10 years. The study was presented at the Annual Meeting of the American Association for Cancer Research in Chicago on April 1, 2012. The study tracked 60,000 nurses taking HRT for 10 years. Results showed that breast cancer risk was 88% higher in women taking estrogen and progesterone for 10 to 15 years compared to non-users. This risk doubled for women who take the therapy for 15 to 20 years. Researchers found that this risk keeps increasing with longer durations of use and it never tapers off. According to Dr. Wendy Chen, author of the study and assistant professor in medicine at the Dana-Farber Cancer Institute in Boston, women should think about the reason they're taking the hormones and explore other options with their doctor. "If it is for hot flashes, they don't last forever," she says. "You are not going to have the systemic effects that you will from taking a pill." Hormone Therapy Increases Breast Cancer Risk